title: Emerging therapies for acute ischemic stroke.
abstract: Stroke is a major public health problem in the United States and the development of novel therapeutic strategies is an important research priority. Advances in this field are proceeding on several fronts, including the use of next-generation plasminogen activators and glycoprotein IIb/ IIIa inhibitors, refined patient selection with advanced magnetic resonance imaging sequences, endovascular approaches to thrombolysis and thrombectomy, and adjuvant use of ultrasound. There remains no proven therapy for intracerebral hemorrhage, but early results with recombinant activated factor VII look very promising. It is hoped that in the near future, physicians managing patients with acute neurological events will have a robust armamentarium of therapies to bring to bear on both ischemic and hemorrhagic vascular disease.
authors.affiliation: Department of Neurosciences, San Diego School of Medicine, University of California, San Diego, CA, USA.
authors.forename: Justin A
authors.initials: JA
authors.lastname: Sattin
authors.forename: Justin A
authors.initials: JA
authors.lastname: Zivin
mesh_terms: D002543:Cerebral Hemorrhage / Q000188:drug therapy / Q000601:surgery*; D005167:Factor VII / Q000627:therapeutic use; D015942:Factor VIIa; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011994:Recombinant Proteins / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy* / Q000601:surgery
chemical_list: D005343:Fibrinolytic Agents; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa